Orca Wealth Management LLC Has $4.87 Million Stock Holdings in AstraZeneca PLC $AZN

Orca Wealth Management LLC lowered its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 69,618 shares of the company’s stock after selling 516 shares during the period. AstraZeneca accounts for 4.1% of Orca Wealth Management LLC’s portfolio, making the stock its 6th biggest holding. Orca Wealth Management LLC’s holdings in AstraZeneca were worth $4,865,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Dynamic Advisor Solutions LLC grew its position in shares of AstraZeneca by 58.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock worth $960,000 after acquiring an additional 4,811 shares during the last quarter. SCS Capital Management LLC bought a new position in shares of AstraZeneca during the first quarter worth about $3,066,000. Robbins Farley bought a new position in AstraZeneca in the 2nd quarter valued at about $1,857,000. Farther Finance Advisors LLC grew its position in AstraZeneca by 13.1% in the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock valued at $442,000 after buying an additional 706 shares in the last quarter. Finally, Oliver Luxxe Assets LLC grew its position in AstraZeneca by 6.0% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after buying an additional 4,449 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $85.31 on Friday. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $85.50. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $264.58 billion, a price-to-earnings ratio of 32.07, a PEG ratio of 1.57 and a beta of 0.36. The firm has a 50-day moving average of $78.04 and a two-hundred day moving average of $73.07.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same period in the prior year, the company earned $1.24 EPS. AstraZeneca’s revenue was up 16.1% on a year-over-year basis. As a group, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were issued a $0.505 dividend. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s dividend payout ratio is presently 37.97%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AZN shares. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research report on Saturday, September 27th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.